KWIK-STIK, Quality control kit for culture media, sold as: KWIK-STIK (single-pack) Enterococc...

FDA Device Recall #Z-0714-2022 — Class II — October 6, 2014

Recall Summary

Recall Number Z-0714-2022
Classification Class II — Moderate risk
Date Initiated October 6, 2014
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Microbiologics Inc
Location Saint Cloud, MN
Product Type Devices
Quantity 150 units

Product Description

KWIK-STIK, Quality control kit for culture media, sold as: KWIK-STIK (single-pack) Enterococcus faecalis derived from ATCC 51299

Reason for Recall

This strain should be resistant to high levels of Gentamicin and be resistant to Gentamicin Synergy. A specific lot was found susceptible to Gentamicin Synergy during in-house testing.

Distribution Pattern

Worldwide distribution - US Nationwide and the countries of Argentina, Belgium, Brazil, Canada, Chile, China, Colombia, Croatia/Hrvatska, Ecuador, Finland, France, Germany, Guam, Guatemala, Hong Kong, India, Ireland, Israel, Italy, Japan, Kenya, Republic of Korea, Latvia, Macedonia, Malaysia, Netherlands, Panama, Peru, Poland, Portugal, Puerto Rico, Romania, Saudi Arabia, Singapore, South Africa, Switzerland, Taiwan, Tanzania, Thailand, Turkey, Uganda, United Arab Emirates, and Vietnam.

Lot / Code Information

Catalog Number HL163263 OEM Private Label with Healthlink; UDI: N/A (OEM agreement with Healthlink ended in Q1 2016 before UDI was required for class 1 IVDs) Lot Number (Expiration Date): 959-74-1 (10/08/2014), 959-75-2 (04/22/2015), 959-75-3 (04/22/2015), 959-75-6 (04/22/2015), 959-75-7 (04/22/2015), 959-75-10 (04/22/2015), and 959-76-2 (07/08/2015)

Other Recalls from Microbiologics Inc

Recall # Classification Product Date
Z-0985-2026 Class II KWIK-STIK 6-Pack, Campylobacter jejuni subsp. j... Dec 2, 2025
Z-0984-2026 Class II KWIK-STIK 2-Pack, Campylobacter jejuni subsp. j... Dec 2, 2025
Z-0986-2026 Class II LYFO DISK, Campylobacter jejuni subsp. jejuni d... Dec 2, 2025
Z-0876-2026 Class II KWIK-STIK, Quality control kit for culture medi... Nov 13, 2025
Z-2194-2025 Class II LYFO-DISK, M. Canis Derived from ATCC 36299, pa... Jun 27, 2025

Frequently Asked Questions

Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.